Sweeping FDA Reforms Successfully Enacted
On July 9th President Obama signed the FDA Safety and Innovation Act (the Act) which contained numerous provisions affecting drug manufacturers, including drug developers/manufacturers of regenerative medicine products. ARM supported many of the Act's provisions and ARM members lobbied on its behalf during this year's ARM Fly In.
The Act included FDA user fees as well as other important reforms.
Below is a summary of key provisions of the legislation.
The bill codifies the negotiated agreement on user fees between the drug industry and FDA. It reauthorizes the prescription drug user fee program allowing the FDA to continue to collect fees from industry to support the review process for human drug applications from fiscal year 2013 through fiscal year 2017. Under the Act, in exchange for fee increases, FDA agrees to:
1. Meet performance goals related to timely review of drug applications
2. Increase interaction with drug sponsors during the review process
3. Expand interactions with patients, including those with rare diseases
4. Evaluate its own performance
In addition, the Act for the first time creates user fees to support reviews of biosimilars ─ new versions of already-marketed biologics ─ as well as for generic drugs.
The Act's changes to the FDA review and approval process for drugs that treat serious or life threatening diseases could speed review of regenerative medicine products. Specifically, the Act requires FDA to facilitate the development and expedite the review of a drug designated as a "fast-track product." These are drugs for the treatment of a serious or life-threatening disease or condition that also demonstrates the potential to address unmet medical needs. In addition, the Act "enhances" the existing accelerated approval process and creates a mechanism whereby the FDA can expedite reviews of marketing applications for drugs that treat serious or life threatening conditions, including fast track products, at the request of the sponsor.
Under the Act, during the accelerated approval process, the FDA can approve a product if it has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit or a clinical endpoint that can be "measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality" or other clinical benefit taking into account the severity or rarity of the disease or condition and the availability of alternative treatments. Accelerated approval may be subject to a sponsor being required to perform post-approval studies and submit promotional materials prior to dissemination.
FDA is required to issue draft guidance implementing this process within one year and a final guidance a year later. In addition, the legislation calls for an independent analysis of accelerated approval and its impact on the development of innovative treatments.
The Act also requires the FDA to expedite the development and review of a drug designated a "breakthrough therapy." To achieve this designation, a drug must be intended to treat a serious or life-threatening disease or condition, and preliminary clinical evidence must indicate that it may demonstrate substantial improvement over existing therapies.
The Act contains several provisions specifically designed to promote drug development for rare diseases. For example, the accelerated approval provisions noted above require FDA to consider the "severity or rarity" of the disease or condition being treated. In addition, when developing its guidance to implement the program, FDA must specifically take into account issues relating to how the process will apply to development of products for very rare diseases for which the low prevalence of a disease makes collecting data difficult. Moreover, under the Act, FDA must ensure that opportunities exist for consultation with external stakeholders from the rare disease community and keep a list of medical experts to consult with during reviews of products for rare diseases.
It is important to note that the Act implements the provisions in the negotiated agreement between FDA and the drug industry that call for employing user fees to address rare disease issues, such as training FDA staff to better handle orphan drug applications. Moreover, FDA is expected to increase rare disease patient and advocate involvement in application reviews and add new staff for outreach to sponsors.
Moreover, the Act creates a program that provides the sponsor of a rare pediatric disease product with a voucher that entitles the sponsor to priority review of any other product (FDA must act on the application within six months). To qualify, the rare pediatric disease product cannot have an adult indication and the disease must primarily impact those up to 18 years of age. Companies that receive a voucher can use it for their own future products or transfer/sell the voucher to another sponsor.
Other Provisions of Note
The Act contained other provisions related to drug development including:
• Requiring FDA to work with other regulatory agencies to reduce duplication of studies necessary for premarket approval, without altering the current standards for premarket review of medical products; FDA must, when considering drug applications, either accept foreign clinical data or notify the sponsor of FDA’s rationale for concluding that the data are not adequate to support approval
• Requiring FDA to establish a strategy and implementation plan for advancing regulatory science
ARM will continue to monitor implementation of these provisions.
- About Us
- Get Involved
- ARM in Action
- About Regenerative Medicine
- Media Center
Save the Date - October 14 -16, 2013 - for regenerative medicine's top three-day conference bringing together both senior members of...
In partnership with the California Institute for Regenerative Medicine (CIRM), ARM is hosting a private, invitation-only event for top...
ARM's 2013 Annual Report is now available for download. This annual publication provides an...